AVID (Anti-VEGF iDrops) Trial
Research type
Research Study
Full title
A Phase I/IIa open-label proof of concept study to assess the safety, tolerability and efficacy of U8:Ranibizumab Eye drops in patients with choroidal neovascularisation
IRAS ID
1011235
Contact name
Saad Younis
Contact email
Sponsor organisation
University College London (UCL)
Eudract number
0000-000000-00
ISRCTN Number
ISRCTN16566739
Research summary
UCL is developing U8:Ranibizumab Eye Drops (the study drug) as a potential treatment for Wet Age-Related Macular Degeneration (AMD), which is where abnormal blood vessels grow in the macula (part of the eye), leading to fluid or blood leakage, rapid damage to central vision, and eventual scarring. Symptoms include distorted vision, blind spots, and difficulty seeing colours.
The current medicine used to treat Wet AMD is given by injection to the eye, which is an uncomfortable and potentially risky procedure for patients. A medicine given as an eye drop would be minimally invasive and would eliminate any side effects caused by the injection procedure.
In this trial, we will investigate whether the study drug causes any important side effects and compare its effectiveness with medicines currently used to treat Wet AMD.
This trial will take place at 1 NHS site in London – the Imperial College Ophthalmology Research Group unit.
We plan to enrol 3 patients aged 60+ who have been diagnosed with Wet AMD. Participants will initially receive 3 doses of the current medicine used to treat Wet AMD and then they will be provided the study drug to self-administer once daily for 12 weeks. Participants will be monitored throughout the trial for any side effects and they will return to the unit every 2 weeks for safety assessments to be performed. Once participants have completed dosing, they will be monitored for a further 4 weeks for any side effects. Participants will return to the unit for one final visit at the end of the follow up period to be discharged from the trial and returned to standard of care treatment.
Participants will be involved in the trial for 28 weeks (7 months) in total, from the first injection of the current medicine until the discharge visit.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
26/LO/0164
Date of REC Opinion
26 Mar 2026
REC opinion
Further Information Favourable Opinion